The therapy is a bispecific antibody about to enter phase 2 studies targeting atopic dermatitis, a common inflammatory skin disease. Pending regulatory approval, J&J expects to acquire the drug candidate from Switzerland-based Numab Therapeutics in the second half of 2024.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
